AS-8112: The new metoclopramide?

[mindcancer]

As far as I'm aware, AS-8112 isn't a drug that you can get your hands on. It hasn't been clinically tested, and it doesn't have a trade name (classified as a "synthetic compound"). AS-8112 antagonizes both the 5-HT3 receptor and the D2 receptor. The focus is on the chemoreceptor trigger zone. The CTZ communicates with the vomiting centre to initiate vomiting. Hormones and drugs travelling to the CTZ via blood can initiate vomiting or make it impossible for it to send signals to the vomiting centre, thus preventing vomiting even if it the body should be. The CTZ communicates via neurons that contain 5-HT3-, D2, H1 & H3 receptors. D2 antagonizers would be optimal, but clearly, 5-HT3 antagonizers work as well. Metoclopramide is superior because it is an antagonizer for both the 5-HT3- and D2 receptors. Tagamet works because it's because it is an H2 receptor antagonist. Domperidone works because it's a D2 receptor antagonist. Ondansetron works because it's a 5-HT3 receptor antagonist. AS-8112 antagonizes both the D2 receptor and the 5-HT3 receptor, so it makes it as potent as metoclopramide. Maybe this "synthetic compound" will be a viable option in the future. Contrary to what Stan's guide claims, D2 antagonizers aren't the only antagonizers that work.

 

[Brick In The Wall]

Sounds like a promising drug. Many experimental drugs never make it out of trials, so I suppose we'll see what comes of it.

 

[mindcancer]

Just to make it clear: H3- & H1 receptor antagonists are only to prevent motion sickness. They will not work with e.g sodium nitrite.